st jude medical inc (STJ) Key Developments
St. Jude Medical Inc. Proposes Amendments to its Articles of Incorporation and Bylaws
Mar 25 15
St. Jude Medical Inc. at the Annual meeting of shareholders to be held on May 7, 2015, proposed amendments to Articles of Incorporation and Bylaws to declassify Board of Directors.
St. Jude Medical Inc. Announces New Champion Data Show Significant Improvement in Survival Rates for Heart Failure Patients with Reduced Ejection Fraction
Mar 15 15
St. Jude Medical Inc. announced a new data analysis from the CHAMPION trial showing that heart failure (HF) patients with reduced ejection fraction on optimal doses of guideline directed medical therapy (GDMT) managed by pulmonary artery (PA) pressure monitoring with the CardioMEMS - HF System had a 57% reduction in mortality and a 43% reduction in HF hospitalizations compared with patients on GDMT managed by the standard of care (SOC). These data show a strong improvement for patients managed by optimal GDMT and the CardioMEMS HF System in both mortality and hospitalizations over currently defined best practices. The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery. The analysis looked at patients with HF and reduced ejection fraction (HFrEF) (when the heart muscle does not contract effectively and less oxygen-rich blood is pumped out to the body) over an average of 17 months who were on optimal GDMT and compared those managed by PA pressure monitoring with the CardioMEMS HF System to those managed by SOC. The CHAMPION trial retrospective analysis demonstrated that PA pressure monitoring, in addition to GDMT, significantly reduced HF hospitalizations and mortality in patients with reduced ejection fraction. The CardioMEMS HF System uses a miniaturized, wireless monitoring sensor that is implanted in the pulmonary artery (the artery that delivers blood from the heart to the lungs) during a minimally invasive procedure to directly measure PA pressure. Measuring PA pressure allows clinicians to proactively manage treatment for patients with worsening HF before visible symptoms, such as weight and blood pressure changes, occur. The system allows patients to transmit PA pressure data from their homes to their health care providers, who then manage appropriate medication changes to reduce the likelihood of hospitalization and improve survival.
St. Jude to Pay $14.5 Million to Settle Riata Lawsuits
Feb 27 15
St. Jude Medical Inc. could pay up to $14.5 million to settle claims over its malfunctioning Riata defibrillator wires. Minnesota Public Radio reports on the disclosure by the med-tech company. It stopped selling the Riata leads in 2010 as reports surfaced the wires were decaying early and breaking through insulation. Faulty defibrillator wires can result in shocking users at the wrong times, or failing to operate when the patient's heart stops.
St. Jude Medical Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 08:00 AM
Feb 27 15
St. Jude Medical Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 08:00 AM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Donald J. Zurbay, Chief Financial Officer and Vice President of Finance.
St. Jude Medical Seeks Acquisitions
Feb 26 15
St. Jude Medical Inc. (NYSE:STJ) is seeking acquisitions. St. Jude Medical has shifted focus to strategic acquisitions and agreements as its key business strategies to increase its share in the Saudi Arabia, South Africa, and Turkish neuromodulation market.